Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?

Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?

Key PointsIovance obtained approval for Amtagvi last year, which has given its top line a big boost.This year, the company anticipates it can generate up to $300 million in sales.Though it's unprofitable, management believes it has adequate liquidity to fund its operations for well over a year.10 stocks we like better than Iovance Biotherapeutics › When a stock is in a seemingly endless tailspin, it can be tough to take a chance and invest in it…